| Drug General Information |
| Drug ID |
D0I8YS
|
| Drug Name |
RO5520985
|
| Drug Type |
Monoclonal antibody
|
| Indication |
Colorectal cancer [ICD9: 153, 154; ICD10:C18-C21]
|
Phase 2 |
[1]
|
|---|
| Company |
Roche
|
| Target and Pathway |
| Target(s) |
Vascular endothelial growth factor A |
Target Info |
Modulator |
[2]
|
|---|
| Angiopoietin-2 |
Target Info |
Modulator |
[2]
|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
HIF-1 signaling pathway
|
|
mTOR signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
VEGF signaling pathway
|
|
Focal adhesion
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
Renal cell carcinoma
|
|
Pancreatic cancer
|
|
Bladder cancer
|
|
Rheumatoid arthritishsa04014:Ras signaling pathway
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
EGFR1 Signaling Pathway
|
|
TGF_beta_Receptor Signaling Pathway
|
|
TSH Signaling Pathway
|
|
Leptin Signaling Pathway
|
|
FSH Signaling PathwayNetPath_7:TGF_beta_Receptor Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
VEGF signaling pathwayP00005:Angiogenesis
|
|
Pathway Interaction Database
|
Glypican 1 network
|
|
HIF-2-alpha transcription factor network
|
|
Beta3 integrin cell surface interactions
|
|
S1P3 pathway
|
|
Signaling events mediated by TCPTP
|
|
S1P1 pathway
|
|
Alpha9 beta1 integrin signaling events
|
|
Integrins in angiogenesis
|
|
VEGFR1 specific signals
|
|
HIF-1-alpha transcription factor networkangiopoietinreceptor_pathway:Angiopoietin receptor Tie2-mediated signaling
|
|
Reactome
|
Platelet degranulation
|
|
Regulation of gene expression by Hypoxia-inducible Factor
|
|
VEGF ligand-receptor interactions
|
|
VEGF binds to VEGFR leading to receptor dimerizationR-HSA-210993:Tie2 Signaling
|
|
WikiPathways
|
SIDS Susceptibility Pathways
|
|
Hypertrophy Model
|
|
Endochondral Ossification
|
|
Focal Adhesion
|
|
Differentiation Pathway
|
|
Bladder Cancer
|
|
Regulation of Hypoxia-inducible Factor (HIF) by Oxygen
|
|
Nifedipine Activity
|
|
Aryl Hydrocarbon Receptor
|
|
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
|
|
Integrated Pancreatic Cancer Pathway
|
|
Oncostatin M Signaling Pathway
|
|
Allograft Rejection
|
|
Integrated Breast Cancer Pathway
|
|
Signaling by VEGF
|
|
Heart Development
|
|
AngiogenesisWP1794:Cell surface interactions at the vascular wall
|
| References |
| REF 1 | ClinicalTrials.gov (NCT02141295) A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer |
|---|
| REF 2 | Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. doi: 10.1038/nrd4478. |
|---|
